

Preliminary
Programme
Preliminary
Programme
Thursday, 17 September 2026
Opening of Day 1
Keynote Lecture
Georg Schett, University Hospital Erlangen, Erlangen, Germany
“Lupus in Remission – A New Immune Reality?”
Keynote Lecture
Georg Schett, University Hospital Erlangen, Erlangen, Germany
“Lupus in Remission – A New Immune Reality?”
Session I: What Have We Learned So Far – T Cell Concepts in Autoimmunity
Tobias Alexander, Charité-Universitätsmedizin Berlin, Berlin, Germany
“Bispecific T Cell Engagers – Bridging Specificity and Safety”
Dominique Farge, Assistance publique – Hôpitaux de Paris, Paris, France
“Resetting the System – Autologous Stem Cell Transplantation Revisited”
Harald Prüß, Charité – Universitätsmedizin Berlin, Berlin, Germany
“From Blunt Force to Precision: CAAR T Cells in Autoimmune Disease”
Chairs:
Dimitrios Mougiakakos, University Hospital Magdeburg, Magdeburg, Germany
Georg Schett, University Hospital Erlangen, Erlangen, Germany
Session II: Autoimmunity Reimagined: Early Clinical Experiences with T Cell Therapy
Aiden Haghikia, Hannover Medical School, Hannover, Germany
“Translating CAR T Cell Therapy into Neuromuscular Diseases”
Everett H Meyer, Stanford University, Stanford, CA, United States
“Regulatory T Cell Therapy in Action: Clinical Insights from GvHD to Autoimmunity”
Franco Locatelli, Bambino Gesù Children’s Hospital, Rome, Italy
“Hit Hard, Hit Early: CAR T Cell Therapy in Children with Autoimmune Disorders”
Jeffrey Dunn, Stanford University, Stanford, CA, United States
“Lessons from MS – Window of Opportunity for T Cell Interventions”
Chairs:
Andreas Mackensen, University Hospital Erlangen, Erlangen, Germany
Sven Meuth, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
Get together
Friday, 18 September 2026
Opening of Day 2
Session III: Engineering & Innovation
Axel Schambach, Hannover Medical School, Hannover, Germany
“Inject, Target, Reprogram: In Vivo CAR T Cells”
Michael Hudecek, University Hospital Würzburg, Würzburg, Germany
“Engineering Lessons from Oncology: Making CAR T-Cell Therapy Accessible and Effective in Autoimmunity”
Chiara Bonini, Ospedale San Raffaele, Milano, Italy TBC
“Redirected Tregs as a Non-Cytotoxic Strategy to Reestablish Immune Homeostasis”
Manuel Juan, Hospital Clinic de Barcelona, Barcelona, Spain
“PoC Manufacturing: can academia compete with pharma?”
Chair:
Ulrike Köhl, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany
Ricardo Grieshaber-Bouyer, University Hospital Erlangen, Erlangen, Germany
Session III: Engineering & Innovation
Axel Schambach, Hannover Medical School, Hannover, Germany
“Inject, Target, Reprogram: In Vivo CAR T Cells”
Michael Hudecek, University Hospital Würzburg, Würzburg, Germany
“Engineering Lessons from Oncology: Making CAR T-Cell Therapy Accessible and Effective in Autoimmunity”
Chiara Bonini, Ospedale San Raffaele, Milano, Italy TBC
“Redirected Tregs as a Non-Cytotoxic Strategy to Reestablish Immune Homeostasis”
Manuel Juan, Hospital Clinic de Barcelona, Barcelona, Spain
“PoC Manufacturing: can academia compete with pharma?”
Chair:
Ulrike Köhl, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany
Ricardo Grieshaber-Bouyer, University Hospital Erlangen, Erlangen, Germany
Session IV: Clinical Implementation & Risk Management
Remy Dulery, Assistance publique – Hôpitaux de Paris, Paris, France
“Secondary Malignancies – Myth or Real Long-Term Concern?”
Melanie Hagen, University Hospital Erlangen, Erlangen, Germany
“New indications – new toxicities?”
Robert Zeiser, University of Freiburg Medical Center, Freiburg, Germany
“Preclinical Models for CRS & ICANS – Lessons Learned”
Rafaela Greco, Ospedale San Raffaele, Milano, Italy
“EBMT Guidelines Revisited: When, who, and how.”
Chair:
Stephan Fricke, University Hospital Magdeburg, Magdeburg, Germany
TBA
Panel Discussion: How Far Can T Cells Go in Autoimmunity?
Ulrike Köhl, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany
Jeffrey Dunn, Stanford University, Stanford, CA, United States
Dominique Farge, Assistance publique – Hôpitaux de Paris, Paris, France
Franco Locatelli, Bambino Gesù Children’s Hospital, Rome, Italy
Dimitrios Mougiakakos, University Hospital Magdeburg, Magdeburg, Germany
Andreas Mackensen, University Hospital Erlangen, Erlangen, Germany
Panel Discussion: How Far Can T Cells Go in Autoimmunity?
Ulrike Köhl, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany
Jeffrey Dunn, Stanford University, Stanford, CA, United States
Dominique Farge, Assistance publique – Hôpitaux de Paris, Paris, France
Franco Locatelli, Bambino Gesù Children’s Hospital, Rome, Italy
Dimitrios Mougiakakos, University Hospital Magdeburg, Magdeburg, Germany
Andreas Mackensen, University Hospital Erlangen, Erlangen, Germany

